The cancer tissue diagnostics market is projected to reach US$ 3,640.87 million by 2031 from US$ 2,538.31 million in 2022; it is estimated to grow at a CAGR of 6.2% from 2022 to 2031.
Cancer tissue diagnostics techniques are used to detect a tumor in malignant tissues. In the last few years, immunohistochemistry (IHC) was used to increase the detection of specific antigens in tumor tissue. With the help of nonfluorescent chromogens, the screening is analyzed with conventional microscopy. There are recent techniques developed for cancer tissue diagnosis. Fluorescence in situ hybridization is used to examine a genetic abnormality in the genome. The hybridized deoxyribonucleic acid (DNA) is examined with particular probes.
The cancer tissue diagnostics market is segmented on the basis of test type and geography. Based on test type, the market is segmented into immunohistochemical tests and in situ hybridization tests. In 2022, the immunohistochemical tests segment held a larger market share. The market in the same segment is also anticipated to grow at a faster rate in the coming years. By geography, the cancer tissue diagnostics market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The market in Asia Pacific is expected to grow at the highest rate during the forecast period owing to the rising prevalence of cancer and the increasing aging population in Asian countries. The Japanese Government has been formulating and laying down multiple initiatives and programs to enhance the quality of cancer treatment and increase awareness regarding cancer in the country. In China, as per data by the WHO, 45,68,754 new cancer cases were detected, and 30,02,899 cancer deaths were recorded in the country in 2021. The cancer tissue diagnostics report offers insights and in-depth analysis of the market, emphasizing parameters such as market trends, technological advancements, market dynamics, and the competitive analysis of the globally leading market players.
Customize This Report To Suit Your Requirement
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Cancer Tissue Diagnostics Market: Strategic Insights

- Get Top Key Market Trends of this report.This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Cancer Tissue Diagnostics Market: Strategic Insights

- Get Top Key Market Trends of this report.This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Market Insights
New Product Launches and FDA Approvals and growing investments in Cancer Tissue Diagnostics to Fuel Cancer Tissue Diagnostics Market During Forecast Period
Most major market players are involved in manufacturing a wide range of cancer diagnostics products offering maximum advantages and early diagnosis. In June 2022, Roche announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results so clinicians can make timely decisions regarding a patient’s care journey.
In March 2022, Illumina launched a new in vitro diagnostic test in Europe designed to profile various cancer mutations and help direct patients to targeted therapies. Thus, the constant technological developments in diagnostics and FDA approvals accelerate the market growth.
Furthermore, tissue diagnostics is crucial in cancer treatment. Cancer tissue diagnostics play a significant role in determining the treatment pace and procedure. Early detection can help reduce the mortality rates of cancer; hence, medical professionals, market players, and government authorities implement new diagnostics and treatment facilities. Thus, the rise in investments and better policies of reimbursement favor the growth of the cancer tissue diagnostics market.
In May 2021, QIAGEN N.V. launched an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with LUMAKRASTM (sotorasib), a newly approved therapy developed and marketed by Amgen Inc. (AMGN). Furthermore, In January 2021, Illumina and Roche signed a 15-year, non-exclusive collaboration agreement designed to realize NGS’ potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. The value of the partnership—which includes in vitro diagnostic (IVD) and companion diagnostics (CDx) initiatives—was not disclosed. In 2021, the company launched AIforia cloud platform that accelerates image processing and provides automated pathology image analysis. Thus, the increasing collaborations and new technological platforms in cancer tissue diagnostics have led to the advent of breakthrough techniques, which are expected to fuel the growth of the market in the coming years.
Test Type-Insights
Based on test type, the cancer tissue diagnostics market is segmented into immunohistochemical tests and in situ hybridization tests. In 2022, the immunohistochemical tests segment held a larger market share. In addition, the market in the same segment is expected to grow at a faster rate in the coming years owing to the cost-effectiveness of the technique. Moreover, the technique is easily accessible, and growth in the number of products based on technology are further expected to drive the segment growth.
Product launches and collaborations are highly adopted strategies by the global cancer tissue diagnostics market players. A few of the recent key market developments are listed below:
- In June 2022, Roche announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results so clinicians can make timely decisions regarding a patient’s care journey.
- In March 2022, Illumina launched a new in vitro diagnostic test in Europe designed to profile various cancer mutations and help direct patients to targeted therapies.
- In May 2021, QIAGEN N.V. launched an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with LUMAKRASTM (sotorasib), a newly approved therapy developed and marketed by Amgen Inc. (AMGN).
- In January 2021, Illumina and Roche signed a 15-year, non-exclusive collaboration agreement designed to realize NGS’ potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. The value of the partnership—which includes in vitro diagnostic (IVD) and companion diagnostics (CDx) initiatives—was not disclosed.
- In June 2021, Agilent Technologies Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-L1 IHC 22C3 pharmDx assay. The assay is approved to identify patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck.
- In June 2021, Thermo Fisher Scientific's Oncomine Dx Target Test received reimbursement coverage from Japan's Ministry of Health, Labour and Welfare. The test is now commercially available in Japan. The reimbursement has helped the company to offer the diagnosis of NSCLC.\
- In May 2021, Roche launched the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody, an in vitro diagnostic ROS1 immunohistochemistry (IHC) assay. The launch has enabled the company to offer better innovative products.
Company Profiles
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc
- Bio Rad Laboratories Inc
- Abbott
- Enzo Life Sciences, Inc
- Agilent Technologies, Inc
- Cancer Genetics Inc
- Merck KGaA (Sigma-Aldrich Co. LLC)
- Danaher Corporation
- Abcam plc.
Cancer Tissue Diagnostics Market Regional Insights
The regional trends and factors influencing the Cancer Tissue Diagnostics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Cancer Tissue Diagnostics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

- Get the Regional Specific Data for Cancer Tissue Diagnostics Market
Cancer Tissue Diagnostics Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2024 | US$ 2.87 Billion |
Market Size by 2031 | US$ 4.36 Billion |
Global CAGR (2025 - 2031) | 6.20% |
Historical Data | 2021-2023 |
Forecast period | 2025-2031 |
Segments Covered |
By Test Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
Cancer Tissue Diagnostics Market Players Density: Understanding Its Impact on Business Dynamics
The Cancer Tissue Diagnostics Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Cancer Tissue Diagnostics Market are:
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Bio Rad Laboratories Inc.
- Abbott
Disclaimer: The companies listed above are not ranked in any particular order.

- Get the Cancer Tissue Diagnostics Market top key players overview
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials

I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
Yukihiko Adachi CEO, Deep Blue, LLC.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Strategic Planning
- Investment Justification
- Identifying Emerging Markets
- Enhancing Marketing Strategies
- Boosting Operational Efficiency
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.















The List of Companies
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Bio Rad Laboratories Inc.
- Abbott
- Enzo Life Sciences, Inc.
- Agilent Technologies, Inc.
- Cancer Genetics Inc.
- Merck KGaA (Sigma-Aldrich Co. LLC)
- Abcam plc.


